News | Peripheral Artery Disease (PAD) | June 07, 2016

Intact Vascular Commences TOBA III European Clinical Trial

Trial studies combination of Intact Vascular’s Tack Endovascular System and Medtronic IN.PACT Admiral drug-coated balloon in the treatment of peripheral artery disease

Intact Vascular, TOBA III clinical study, Europe, Tack Endovascular System, peripheral artery disease, PAD

June 7, 2016 — Intact Vascular Inc. announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has commenced enrollment, with the first patient treated by Prof. Klaus Brechtel at the Franziskus-Hospital in Berlin, Germany.

The TOBA III study is a prospective, multi-center, single-arm study designed to investigate the safety and efficacy of the Tack Endovascular System in combination with the Medtronic Admiral drug-coated angioplasty balloon in the treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries. The Tack Endovascular System is a new technology designed to repair dissections (or tears) in the artery wall that frequently occur as a complication of balloon angioplasty. The system allows physicians to repair these dissections while leaving a minimal amount of foreign material in the artery, reducing mechanical stress on the artery, and preserving future treatment options.

Brechtel stated, “One of our key goals when using drug coated balloons to perform peripheral angioplasty is to minimize inflammation of the treated artery and leave little foreign material behind. The Tack system is designed to allow us to repair arterial damage after angioplasty while minimizing vessel irritation and leaving far less metal behind than we would with the traditional stenting approach.”

The TOBA III study will be conducted at multiple sites across Europe and will enroll 200 patients in total, including a subgroup of patients with long arterial lesions. Eligible patients will have PAD treated with balloon angioplasty using the Medtronic IN.PACT Admiral Drug-Coated Balloon and have a dissection in the artery wall immediately following angioplasty.

Brechtel continued, “The TOBA III trial will provide us with valuable information about the combination of two very promising technologies designed to treat PAD. We are thrilled to be the first center to begin enrollment in this important study.”

Intact Vascular is also sponsoring the TOBA II study, which is investigating the combination of the Tack Endovascular System with uncoated angioplasty balloons and the Bard Lutonix Drug-Coated Balloon in patients with superficial femoral and popliteal artery disease. Future plans include conducting the TOBA II BTK clinical trial to assess the performance of the Tack Endovascular System following balloon angioplasty in patients with arterial disease below the knee.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init